drugset / Trial / NCT03795142
A First-time-in-human Study of BGB149
RandomizedSequentialQuadruple-blindScreening
Summary
This clinical trial is a Phase I, first-in-human. The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of BGB149 after single IV doses in healthy male and female subjects. Multiple dose levels will be explored.
Timeline
- Start
- 2018-12-19
- Primary completion
- 2019-10-31
- Completion
- 2019-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tilvestamab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.